PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Настройки учетной записи
    • Выйти
    • Войти
    • Зарегистрироваться

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20170730 183458
20180814 175743
DJI 0040
20170731 215853
20180131 184204
20170730 175519
  • Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Carcinoma, Renal Cell, Date of authorisation: 25/08/2016, Revision: 18, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
  • Identification of Medicinal Products — Implementation and Use
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Newly Added Guidance Documents
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Contraceptives, Oral, Date of authorisation: 19/05/2021, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
  • Human medicines European public assessment report (EPAR): Grasustek, pegfilgrastim, Neutropenia, Date of authorisation: 20/06/2019, Revision: 4, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
  • Summary of opinion: Pedmarqsi,sodium thiosulfate, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Summary of opinion: Omvoh,mirikizumab, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Procter & Gamble Manufactura S. de R.L. de C.V. - 650837 - 03/27/2023
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Procter & Gamble Manufactura S. de R.L. de C.V. - 650837 - 03/14/2023
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Summary of opinion: Tenkasi (previously Orbactiv),oritavancin, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Summary of opinion: Ultomiris,ravulizumab, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Summary of opinion: Ultomiris,ravulizumab, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Summary of opinion: Neparvis,sacubitril,valsartan, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Summary of opinion: Entresto,sacubitril,valsartan, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Summary of opinion: Sugammadex Adroiq,sugammadex, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
Предыдущие записи
Тема: Scaffold от Danny Cooper.